We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Triple Antibody Test for COVID-19 Provides Laboratory-Standard Results in Just Seven Minutes

By HospiMedica International staff writers
Posted on 10 Jul 2020
Print article
Image: Triple Antibody Test for COVID-19 Provides Laboratory-Standard Results in Just Seven Minutes (Photo courtesy of Attomarker Ltd.)
Image: Triple Antibody Test for COVID-19 Provides Laboratory-Standard Results in Just Seven Minutes (Photo courtesy of Attomarker Ltd.)
A new triple antibody test detects antibodies to three different COVID-19 proteins in seven minutes at the PoC, giving a more powerful profile of the clinically relevant biomarkers than other currently available COVID-19 tests.

The next-generation test has been developed by Attomarker Ltd. (Devon, UK), a spin-out company from the University of Exeter. Attomarker’s technology uses a multiplex platform, which means that it tests for multiple clinically relevant biomarkers against the SARS-CoV-2 virus simultaneously: Attomarker tests for three virus proteins (Spike 1, Spike 2 & N) and three classes of antibodies (IgM, IgG and IgA), giving a more powerful profile of the patient’s immune response to COVID-19. This could help validate a COVID-19 vaccine when a viable candidate completes development.

Further testing of the multiplex technology is currently underway, trialling a combined COVID-19/flu antibody test in order to help healthcare professionals discriminate between the two infections. Attomarker’s technology is now being further developed into a miniaturized hand-held device, docked to a smartphone, to provide the same quantitative accuracy in the community at point-of-care, including care homes, and pharmacies.

The triple antibody test has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK, following positive results from an initial patient study in which it detected antibodies in a real cohort of recovering patients with a sensitivity of 96%, 14 days after the onset of symptoms.

“This technology tests for antibodies against three viral proteins, two spikes and the nucleocapsid, as well as three classes of antibody, showing quantitative results,” said Professor Sir Robert Lechler, Senior Vice President/Provost (Health) Kings College London. “These differentiators will be key to beginning the next phase of COVID-19 testing urgently needed in the UK, equipping healthcare professionals initially with the data they need to better manage the epidemic.”

“This is the next generation of antibody tests, giving rapid laboratory level results on three classes of antibody in seven minutes and all at point of care. It is another success story for British universities and British science in the global battle against COVID-19,” said Professor Andrew Shaw, CEO & Founder of Attomarker and Associate Professor of Physical Chemistry at the University of Exeter.

Related Links:
Attomarker Ltd.

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Single Cavity Combination Warmer
EC550BL

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Surgical Techniques

view channel
Image: The living replacement knee will be tested in clinical trials within five years (Photo courtesy of ARPA-H)

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Osteoarthritis is the most prevalent type of arthritis, characterized by the progressive deterioration of cartilage, or the protective tissue covering the bone ends, resulting in pain, stiffness, and impaired... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.